News
IRME
0.022
NaN%
--
IR-Med Amends Executive Compensation Amid Financial Struggles
TipRanks · 12/12/2025 21:34
IR-MED Inc. Delays Q3 2025 Financial Report
Reuters · 12/12/2025 21:06
IR-MED Ltd. Announces Launch of First-in-Human Clinical Trial of Its DiaSafe(TM) Device for Diabetic Foot Ulcer (DFU) Assessment
Newsfile · 11/03/2025 21:30
IR-MED Unveils Clinical Results for PressureSafe AI-Powered Skin Assessment Platform
Reuters · 10/27/2025 20:08
IR-MED's Key Clinical and Media Milestones
Newsfile · 10/27/2025 20:05
IR-MED Inc. Completes Private Placement Offering, Issuing 1.56M Shares and Warrants for Additional 781K Shares, CEO Purchases Significant Stake
Reuters · 09/23/2025 15:16
IR-Med Completes Private Placement Offering
TipRanks · 09/22/2025 12:31
IR-MED Inc. Announces New Clinical Trial at Major U.S. Hospital for PressureSafe™ Device, Targeting Broader Adoption in Healthcare Market
Reuters · 09/16/2025 20:06
IR-MED Investor Update Letter - Sept-2025
Newsfile · 09/16/2025 20:05
Weekly Report: what happened at IRME last week (0908-0912)?
Weekly Report · 09/15/2025 10:51
IR-Med Converts Debt into Equity Shares
TipRanks · 09/11/2025 20:37
IR-MED Inc. Announces Conversion of Outstanding Debt into Shares, Fully Satisfying Loan Obligations
Reuters · 09/11/2025 20:06
Weekly Report: what happened at IRME last week (0901-0905)?
Weekly Report · 09/08/2025 10:53
IR-Med Completes Private Placement Offering
TipRanks · 09/03/2025 10:32
IR-MED Inc. Secures $64,754 in Private Placement Offering with Director Investments
Reuters · 09/03/2025 10:05
Weekly Report: what happened at IRME last week (0825-0829)?
Weekly Report · 09/01/2025 10:49
Weekly Report: what happened at IRME last week (0818-0822)?
Weekly Report · 08/25/2025 10:57
Weekly Report: what happened at IRME last week (0811-0815)?
Weekly Report · 08/18/2025 10:51
Weekly Report: what happened at IRME last week (0804-0808)?
Weekly Report · 08/11/2025 10:57
IR-Med Announces Termination of Chief Development Officer
TipRanks · 08/07/2025 20:56
More
Webull provides a variety of real-time IRME stock news. You can receive the latest news about Ir-Med Inc through multiple platforms. This information may help you make smarter investment decisions.
About IRME
IR-Med, Inc. is in the process of developing point-of-care decision support devices based on a patented infrared spectroscopy and artificial intelligence (AI) analysis technology platform. PressureSafe, the Company’s first product based on this platform, is a handheld device designed to revolutionize the assessment of pressure injuries (PI) affecting skin and underlying tissue. The Company is developing its technology through its subsidiary and is utilizing Infra-Red-light spectroscopy (IR) combined with an artificial intelligence (AI) technology platform to develop non-invasive devices for various medical indications, by assessing various biomarkers and molecules in the blood and in human tissue in real-time. The second product candidate, DiaSafe, which is under development, is a non-invasive, user-friendly device which is designed to address medical needs by offering assessment of Diabetic Foot Ulcer (DFU) before skin breakage.